Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Sanofi Dividend Announcement
• Sanofi announced a semi annually dividend of $1.48 per ordinary share which will be made payable on 2024-06-06. Ex dividend date: 2024-05-09
• Sanofi annual dividend for 2024 was $1.48
• Sanofi annual dividend for 2023 was $3.42
• Sanofi's trailing twelve-month (TTM) dividend yield is 3.32%
• Sanofi's dividend growth over the last five years (2018-2023) was 12.94% year
• Sanofi's dividend growth over the last ten years (2013-2023) was -11.90% year
Sanofi Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-05-09 | $1.48 | semi annually | 2024-06-06 |
2023-05-30 | $2.04 | semi annually | 2023-06-23 |
2023-05-25 | $1.38 | semi annually | 2023-06-23 |
2022-05-26 | $0.32 | semi annually | 2022-06-27 |
2022-05-04 | $1.84 | semi annually | 2022-05-31 |
2021-05-03 | $1.93 | semi annually | 2021-05-26 |
2020-04-30 | $1.75 | semi annually | 2020-05-26 |
2019-05-07 | $1.74 | semi annually | 2019-05-31 |
2018-05-09 | $1.86 | semi annually | 2018-06-04 |
2017-05-11 | $1.58 | semi annually | 2017-06-07 |
2016-05-05 | $1.63 | semi annually | 2016-06-01 |
2015-05-06 | $1.62 | semi annually | 2015-06-02 |
2014-05-07 | $2.64 | semi annually | 2014-06-05 |
2013-05-06 | $12.15 | semi annually | 2013-06-05 |
Sanofi Dividend per year
Sanofi Dividend growth
Sanofi Dividend Yield
Sanofi current trailing twelve-month (TTM) dividend yield is 3.32%. Interested in purchasing Sanofi stock? Use our calculator to estimate your expected dividend yield:
Sanofi Financial Ratios
Sanofi Dividend FAQ
Other factors to consider when evaluating Sanofi as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Sanofi stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Sanofi's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Sanofi publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Sanofi distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Sanofi are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Sanofi sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Sanofi distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Sanofi declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Sanofi's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Sanofi's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.